drugset / Trial / NCT01153711

Relative Bioavailability of of Olodaterol and Ketoconazole

NCT01153711

Phase 1 Completed 32 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial is intended to investigate a possible effect of the p-gp inhibitor ketoconazole on the bioavailability of olodaterol

Timeline

Start
2010-05
Primary completion
2010-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule 400 mg Oral
Subject Olodaterol Small molecule 10 ug Inhaled